The findings of the SOLE trial have just been published in Lancet Oncology with Dr Seamus O’Reilly, consultant medical oncologist at Cork-Mercy and South Infirmary Victoria University Hospitals as one of the authors. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
In postmenopausal women with hormone receptor-positive breast cancer, extended use of intermittent
letrozole did not improve disease-free survival compared with continuous use of letrozole. An alternative schedule of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might be feasible and the results of the SOLE trial support the safety of temporary treatment breaks in selected patients who might require them.